Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
Jiwoo Lee, Yun Kyung Cho, Hwi Seung Kim, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of KoreaCorrespondence: Woo Je LeeDepartment of Internal Medicine, Asan Medical Center, University of Ul...
Guardado en:
Autores principales: | Lee J, Cho YK, Kim HS, Jung CH, Park JY, Lee WJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eda4de41ef8a4968ab3fefda593b8b45 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson AM, et al.
Publicado: (2016) -
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell R, et al.
Publicado: (2019) -
Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018) -
Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
por: Kutoh Eiji, et al.
Publicado: (2019) -
Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
por: Marina V. Shestakova, et al.
Publicado: (2017)